688314.SHG Kontour (Xi'an) Medical Technology Co. Ltd.
- Market cap
- CNY 2.13B
- P/E
- 25.1x
- P/B
- 2.76x
- ROE
- 10.8%
- Dividend yield
- 1.54%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688314.SHG undervalued?
Graham number688314.SHG trades 75.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kontour (Xi'an) Medical Technology Co. Ltd. fundamental analysis
No fundamental analysis for Kontour (Xi'an) Medical Technology Co. Ltd. yet.
Kontour (Xi'an) Medical Technology Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kontour (Xi'an) Medical Technology Co. Ltd.
Kontour (Xi'an) Medical Technology Co., Ltd. engages in the research and development, production, and sale of Class III implantable medical devices in China. The company offers products in the fields of neurosurgery cranial repair and fixation, cardiothoracic surgery sternum fixation, and maxillofacial repair. It also provides oral bone repair materials, oral absorbable biofilm, implant system, and other tools. In addition, the company offers repair and fixation products tha…
Full company profileKontour (Xi'an) Medical Technology Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kontour (Xi'an) Medical Technology Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 72.5M | 110M | 148M | 164M | 213M | 240M | 275M | 322M | 350M | 347M |
| Gross Profit | 49.9M | 82.7M | 116M | 132M | 171M | 190M | 215M | 254M | 350M | 268M |
| Operating Income | 11.6M | 23.4M | 60.2M | 51.8M | 86.3M | 86.3M | 91.4M | 106M | 111M | 95.5M |
| EBITDA | 16.2M | 29.9M | 66.2M | 65.1M | 103M | 99.7M | 104M | 120M | 127M | 92.3M |
| Net Income | 10.1M | 22.2M | 51.9M | 52.4M | 81.6M | 75.7M | 75.5M | 88.4M | 98.8M | 81.7M |
| EPS | 0.17 | 0.37 | 0.87 | 0.86 | 1.12 | 0.93 | 0.93 | 1.09 | 1.22 | 1.01 |
| Balance Sheet | ||||||||||
| Total Assets | 129M | 156M | 228M | 292M | 573M | 638M | 676M | 747M | 909M | 933M |
| Total Liabilities | 26.7M | 28.3M | 35.8M | 48.5M | 72.0M | 96.5M | 84.3M | 109M | 185M | 172M |
| Shareholders' Equity | 100M | 126M | 193M | 245M | 503M | 543M | 587M | 636M | 718M | 755M |
| Cash & Short-term Investments | 40.2M | 20.6M | 112M | 92.8M | 325M | 349M | 375M | 379M | 374M | 141M |
| Total Debt | 136K | 3.98M | 8.12M | 14.1M | 23.0M | 38.9M | 39.0M | 44.9M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 11.3M | 22.8M | 57.8M | 57.8M | 103M | 92.0M | 88.5M | 140M | 118M | - |
| Capital Expenditure | 985K | 4.05M | 9.49M | 73.0M | 55.2M | 18.2M | 14.2M | 47.4M | 51.4M | 40.3M |
| Free Cash Flow | 10.3M | 18.8M | 48.3M | -15.1M | 48.0M | 73.8M | 71.0M | 92.9M | 66.7M | 65.2M |
| Ratios | ||||||||||
| ROE | 10.1% | 17.5% | 27.0% | 21.4% | 16.2% | 13.9% | 12.9% | 13.9% | 13.8% | 10.8% |
| ROA | 7.8% | 14.2% | 22.7% | 18.0% | 14.2% | 11.9% | 11.2% | 11.8% | 10.9% | 8.8% |
| Net Profit Margin | 13.9% | 20.2% | 35.1% | 31.9% | 38.4% | 31.5% | 27.5% | 27.5% | 28.3% | 23.6% |
| Debt to Equity | 0.00x | 0.03x | 0.04x | 0.06x | 0.05x | 0.07x | 0.07x | 0.07x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kontour (Xi'an) Medical Technology Co. Ltd. dividends
- Dividend yield
- 1.54%
- Forward dividend
- 0.47 CNY
- Payout ratio
- 33.2%
- Ex-dividend date
- Sep 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 32.8M | 0.40 | 33.2% |
| 2024 | CNY 42.7M | 0.53 | 48.3% |
| 2023 | CNY 31.8M | 0.39 | 42.1% |
| 2022 | CNY 36.0M | 0.44 | 47.5% |
| 2021 | CNY 30.2M | 0.41 | 37.0% |
| 2020 | CNY 331K | 0.01 | 0.6% |
| 2019 | CNY 317K | 0.01 | 0.6% |
| 2018 | 21.6K | 0.00 | 0.1% |
| 2017 | 20.2K | 0.00 | 0.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Apr 27, 2023.
Who owns Kontour (Xi'an) Medical Technology Co. Ltd.
- Insiders 63.44%
- Institutions 4.68%
- Public & others 31.88%
- Shares outstanding 81.6M
- Free float 29.7M
Kontour (Xi'an) Medical Technology Co. Ltd. company profile
- Company name
- Kontour (Xi'an) Medical Technology Co. Ltd.
- Ticker
- 688314.SHG
- ISIN
- CNE1000077Y8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 380
- Fiscal year end
- December
- Address
- No. 1451, West Section of Biyuan 1st Road, Xi'an, China, 710065
- Website
- kontourmedical.com
About Kontour (Xi'an) Medical Technology Co. Ltd.
Kontour (Xi'an) Medical Technology Co., Ltd. engages in the research and development, production, and sale of Class III implantable medical devices in China. The company offers products in the fields of neurosurgery cranial repair and fixation, cardiothoracic surgery sternum fixation, and maxillofacial repair. It also provides oral bone repair materials, oral absorbable biofilm, implant system, and other tools. In addition, the company offers repair and fixation products that include traditional titanium materials, high-end PEEK materials, and absorbent polymer materials; PEEK4D bioactive plates; PEEK bone plates, titanium mesh plates, PEEK link plates, PEEK screws, titanium link plates, test molds, bone plugs, bone mesh, bone plug strips, disposable brain drainage devices, supporting surgical tools, and other complete products for skull repair and fixation surgery process. Kontour (Xi'an) Medical Technology Co., Ltd. was founded in 2005 and is based in Xi'an, China.
Kontour (Xi'an) Medical Technology Co. Ltd. management
7- Mr. Hailong ZhuGM & Director · born 1976
- Mr. Liang ShenChief Financial Officer · born 1979
- Mr. Ruoyu ZhaoDirector & Deputy GM · born 1978
- Ms. You WuDeputy GM & Director · born 1982
- Ms. Huan ZhouBoard Secretary · born 1988
- Ms. Wei Wei ShangDeputy General Manager · born 1980
- Ming DuAccounting Supervisor